

Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

Yvonne Y. Li^{1,2}, Glenn J. Hanna³, Alvaro C. Laga⁴, Robert I. Haddad^{1,5,6}, Jochen H. Lorch^{1,5,6}, and Peter S. Hammerman^{1,5,6}

Abstract

Purpose: A rare 5% of cutaneous squamous cell carcinomas (cSCC) metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent genomic alterations in this little-studied population of metastatic cSCCs.

Experimental Design: We performed targeted sequencing of 504 cancer-associated genes on lymph node metastases in 29 patients with cSCC and identified mutations and somatic copy-number alterations associated with metastatic cSCC. We determined significantly mutated, deleted, and amplified genes and associated genomic alterations with clinical variables.

Results: The cSCC genome is heterogeneous with widely varying numbers of genomic alterations and does not appear to be associated with human papillomavirus. We found previously identified recurrently altered genes (*TP53*, *CDKN2A*,

NOTCH1/2) but also a wide spectrum of oncogenic mutations affecting RAS/RTK/PI3K, squamous differentiation, cell cycle, and chromatin remodeling pathway genes. Specific mutations in known oncogenic drivers and pathways were correlated with inferior patient outcomes. Our results suggest potential therapeutic targets in metastatic cSCC, including *PIK3CA*, *FGFR3*, *BRAF*, and *EGFR*, similar to those reported in SCCs of the lung and head and neck, suggesting that clinical trials could be developed to accrue patients with SCCs from multiple sites of origin.

Conclusions: We have genomically characterized a rare cohort of 29 metastatic cSCCs and identified a diverse array of oncogenic alterations that can guide future studies of this disease. *Clin Cancer Res*; 21(6); 1447–56. ©2015 AACR.

Introduction

Nonmelanoma skin cancers are the most common type of cancer in the United States, with over 3.5 million new cases diagnosed annually (1). Cutaneous squamous cell carcinoma (cSCC) comprises 20% of these cases, and its incidence is continuing to rise (2). Ninety-five percent of cSCCs are curable with surgical resection; however, 5% metastasize—usually to nearby lymph nodes—leading to a 3-year disease-free survival rate of 56% (3) and a 5-year survival rate of 25% to 35% (4–7). Therapies for patients with metastatic cSCCs are lacking and have been limited by a lack of knowledge of the genomic alterations that drive metastatic cSCCs. In addition, there are no validated molecular biomarkers predictive of disease behavior or treatment response.

Numerous risk factors for the development of cSCC have been identified, including exposure to ultraviolet radiation, ionizing agents, and chemical carcinogens (8). Approximately 65% of cSCCs arise from premalignant precursor conditions such as actinic keratosis (9). Organ transplant recipients on immunosuppression regimens are 65 times more likely to develop cSCC (10). Human papillomavirus (HPV) infection has also been associated with increased risk in developing cSCC (11), and patients on chemotherapy targeting BRAF frequently develop cSCCs with RAS mutations (12). The risk factors for developing metastases are less characterized, with an analysis of 615 patients showing only tumor thickness associated with a significant risk of metastasis (13). A second study found that a combination of risk factors (tumor diameter, differentiation histology, perineural invasion, and tumor invasion) improved upon previous staging systems to predict clinically aggressive cSCCs with poor outcome (14).

Genomic characterization of cSCC has mostly been performed on small cohorts of samples. Exome analysis of 8 and 11 primary patient tumors, respectively, identified a large mutational burden of 33.3 mutations per megabase (Mb) of coding sequence, recurrent *TP53* mutations and copy-number loss (15), and recurrent *NOTCH* family loss-of-function mutations (16). SNP array analysis of 60 tumors identified loss of heterozygosity at 3p and 9p in 65% to 75% of the samples (17). Targeted analysis of the *CDKN2A* locus in 40 samples identified alterations (mutation, copy loss, promoter methylation) in 76% of cases (18). Microarray comparison of 10 actinic keratosis and 30 cSCC samples identified several MAPK pathway genes significantly overexpressed in the malignant samples (19). Similar findings were reported by studies involving larger cohorts of primary cSCCs: targeted sequencing of the known *NOTCH1/2*, *TP53*, *CDKN2A*,

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ²Broad Institute, Cambridge, Massachusetts. ³Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. ⁴Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. ⁵Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. ⁶Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

J.H. Lorch and P.S. Hammerman contributed equally to this article.

Corresponding Authors: Peter S. Hammerman, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-852-6224; Fax: 617-582-7880; E-mail: Peter_Hammerman@dfci.harvard.edu; and Jochen H. Lorch, Phone: 617-632-3090; Fax: 617-632-4448; E-mail: Jochen_Lorch@dfci.harvard.edu

doi: 10.1158/1078-0432.CCR-14-1773

©2015 American Association for Cancer Research.

Translational Relevance

The vast majority of cutaneous squamous cell carcinomas (cSCC) are treated effectively with simple surgical excision. However, in approximately 5% of cases, metastatic disease develops and is associated with very poor clinical outcomes. There are no therapies approved by the FDA with a specific indication for metastatic cSCC and development of novel agents has been slow, likely due to a limited knowledge of the molecular basis of this disease. Here, we performed a next-generation sequencing study of 29 individuals with metastatic cSCC to describe the key genomic alterations in cSCC and enumerate potential therapeutic targets. We identify multiple genes that display recurrent mutation, amplification, and deletion in this disease, including several alterations which have been or are being pursued as therapeutic targets in other cancer types. Together, our data present an initial genomic portrait of metastatic cSCCs and suggest that patients with this disease may benefit from biomarker-associated therapeutic agents under evaluation in other cancers, namely squamous cell carcinomas of the lung and head and neck.

and *RAS* genes on 132 cSCCs that developed sporadically and 39 cSCCs that developed after BRAF-inhibitor treatment (20), and exome sequencing of 39 clinically aggressive cSCC primaries (21). Recently, missense mutations in the kinetochore-associated protein *KNSTRN* have emerged as a novel potential driver of cSCC, recurring in approximately 19% of cSCC cases (22). Genomic understanding of metastatic cSCCs is limited, though *VEGFA* overexpression has been linked to lymphatic metastasis in mouse models (23).

The evaluation of biomarker-driven targeted therapies in cSCCs has been limited. Most trials are exploring EGFR-targeted therapy, as advanced tumors often show upregulated *EGFR* expression without *RAS* mutations (24, 25)—observations similar to those made in SCCs of the head and neck and lung. However, some studies have found no correlation of *EGFR* overexpression with the malignant phenotype (26). Clinical activity of *EGFR* antagonists in cSCCs has been observed, with a surprising 18% complete response rate in a phase II trial of gefitinib (27), suggesting that further refinement of the subset of patients with cSCC likely to respond to EGFR therapy is needed. A more comprehensive understanding of metastatic SCC is necessary to identify genomic characteristics and target pathways for this aggressive disease. Here, we sequenced 29 cSCC lymph node metastases to search for recurrent genomic alterations and better define potential avenues for clinical trial development and therapy.

Materials and Methods

Sample selection and sequencing

Cases of cSCC with lymph node metastases were identified from the Dana-Farber Cancer Institute-Harvard Cancer biorespository in accordance with standards established by the Institutional Review Board (IRB). All cases underwent a secondary review by a Board-Certified dermatopathologist who verified the diagnosis and identified the optimal portions of the section for isolation of tumor DNA and DNA from adjacent normal areas. Tissue from these areas was isolated from the formalin-fixed

paraffin-embedded (FFPE) block using a small bore punch biopsy needle, and the resultant cores were used for DNA isolation using the Qiagen FFPE DNA extraction Kit. DNA was quantified and quality controlled by Nanodrop and pico-Green assays before library construction.

Samples were sequenced using the OncoPanelv2 platform (28, 29), a targeted Illumina sequencing strategy aimed to simultaneously detect mutations, translocations, and copy-number variations in archived clinical tumor specimens. Targeted sequencing was achieved by designing RNA baits to capture the exons of 504 genes with relevance to cancer. The bait set was augmented with specific intronic sequences to detect translocations often involved in cancer. Sequencing was performed using 100 bp reads on an Illumina HiSeq 2500. The reads were aligned to human reference genome b37 using Picard and the Firehose pipeline at the Broad Institute. The BAM files are in the process of being submitted to dbGAP.

Relevant de-identified clinical data were abstracted from the patient charts in accordance with an IRB-approved protocol.

Variant calling

Variant calling (SNVs, indels) was performed using the Firehose pipeline running Mutect (30) and filtering out OxoG artifacts. We also removed likely germline mutations that were previously seen in both dbSNP build 134 and 1000 Genome data using Oncotator (<http://www.broadinstitute.org/oncotator/>; refs. 31–35). Significance analysis was conducted using MutsigCV, Mutsig2.0, and Mutsig1.5, which incorporate different methods of calculating background mutation rates. Mutsig 1.5 estimates background rate using synonymous mutations. Mutsig2.0 estimates enrichment of mutations at evolutionarily conserved positions and the clustering of mutations at gene hotspots. Finally, MutSigCV considers gene expression, replication time, and chromatin state when calculating background rate. Given that we started with a set of cancer genes, we took a less stringent approach to the analysis: we ran all three versions of Mutsig and considered the most significant value from the three methods.

We considered mutations overlapping positions in the Catalog of Somatic Mutations in Cancer (COSMIC) database more likely to be cancer-associated. To lower the noise of this analysis, we only considered mutations seen in at least three cancer samples in COSMIC. For nonsynonymous mutations in oncogenes, we performed a detailed literature search to determine whether these mutations had previously been functionally validated *in vitro*.

Copy-number analysis was performed using Nexus7.5 (BioDiscovery Inc) after calculating the sequencing coverage using GATK tools. Coverages were normalized over GC-content using lowess regression, and log2 ratios of coverage were calculated using a best fit reference that resulted in the lowest variance. Copy-number alterations (CNA) were called using the following next-generation sequencing settings: significance threshold of $1E-4$; no maximum contiguous probe spacing; at least six probes per segment; CNAs with a log ratio greater than 0.3 were called gains and greater than 0.6 were called high gains; the single copy loss threshold was set at -0.5 and high loss was -1 . X/Y chromosomes were not analyzed.

Recurrent copy-number changes were detected using GISTIC 2.0 (36). We provided the segments covered by the OncoPanel platform, and set segments for the rest of the genome to be copy neutral. We then used GISTIC to search for peaks of copy-number recurrence in covered areas of the genome. To reduce noise

generated by the many discontinuous segments, which would more easily appear significant against the neutral background of the untargeted genome, we chose to apply GISTIC's arm-level peel correction which has previously been used in a similar setting where multiple discontinuous segments were causing noisy GISTIC peaks (37). We also increased the minimum segment size from 4 to 6 to encourage joining of Oncopanel segments.

Pathway analysis

To calculate recurrent percentages, we considered an alteration to be activating if it landed in a known oncogene and was either a known activating mutation based on literature search or highly amplified. Similarly, we considered alterations to be inactivating if they were nonsense mutations or homozygous deletions. Missense or other nonsynonymous mutations in COSMIC were taken into consideration as a mutations of unknown functional effect but potentially associated with cancer. Missense mutations not present in COSMIC and were not previously validated in the literature were not included.

Statistical analysis

Statistical analyses to test for correlation between genomic and clinical features were performed using standard R packages. We used the Fisher exact test for discrete variables, the log-rank test for continuous variables, and the Bonferroni method of multiple testing correction.

Results

Clinical characteristics of the metastatic cSCC cohort

We sequenced DNA from 29 cSCCs, 26 with matched normal skin, to determine somatic CNAs and mutations (SNVs) in these tumors. All samples were lymph node metastases, with available clinical and survival data (Table 1). The primary tumors were predominantly of the head and neck, with the parotid gland being the most frequent site of metastasis. There were 19 males and 10 females, with median age of 74 at diagnosis of metastatic cSCC. Eleven of the patients subsequently developed recurrent disease, with an average progression-free survival (PFS) of 37 months. Twelve patients (41%) were recurrence-free at 3 years, slightly lower than the previously observed disease-free survival rate of

56%. The samples were also independently validated to be HPV-negative by a combination of p16 immunohistochemistry and hybrid-capture-based DNA sequencing of HPV *E6* and *E7* genes (Pathogenica).

Landscape of genomic alterations

We performed targeted sequencing of 504 cancer-associated genes on the cohort to an average fold coverage of $82\times$ (range, $25\text{--}166\times$) in the tumor samples and $69\times$ (range, $15\text{--}219\times$) in the normal samples, and identified somatic SNVs and CNAs. C→T transition mutations were the dominant substitution, constituting 67% of the mutation spectrum, consistent with the role of UV light exposure in this disease. UV light damages DNA by forming covalent links between adjacent pyrimidines (38), consistent with our observation that 87% of the C→T transitions occurred after a pyrimidine. We did not observe a high rate of the TpC→G mutation type, which has been previously described in HPV and other virally driven cancers (39).

A genomic overview of SNVs and CNAs is shown in Fig. 1A. The two stacked histograms show the number of each type of SNV and CNA per sample, and the coverage plot shows the average sequencing depth achieved per sample. The 26 paired samples had fewer SNVs on average (59 nonsynonymous mutations per sample) compared with the three unpaired samples (117 nonsynonymous mutations per sample), and likely more accurately reflect the mutation rate in this tumor type given an enhanced ability to filter contaminating germline events. The average mutation rate across the 504 sequenced genes was 33 per Mb in the paired samples, varying highly (4–117 per Mb) depending on the sample.


In contrast with SNV rates, CNA rates did not appear dependent on the presence of a matched normal sample when following standard filtering procedures optimized to remove germline copy-number variants. The number of genes with CNAs also varied highly: 2 samples had no genes altered, whereas 6 samples had over 200 genes altered. There was no correlation between the total number of SNVs and CNAs in each sample and the depth of coverage, suggesting that the variation may be biologically based and not confounded by tumor cellularity. Overall, metastatic cSCC appears to be a genomically complex and heterogeneous disease, with large differentials in mutation rate and allelic imbalance across the samples. The full list of SNVs and CNAs is supplied in Supplementary Tables S1 and S2.

Overview of SNV alterations

Figure 1B depicts recurrently mutated genes in metastatic cSCC which exhibited statistical evidence of selection for mutation as determined by the Mutsig algorithm (40) or which did not reach statistical significance but have well-annotated roles in other cancer types. Mutsig is a computational tool that examines gene-specific background mutation rates and assigns significance based on whether a gene is mutated at a probability higher than chance given the mutational patterns observed in the dataset. The table is ordered by number of recurrences and includes previously identified cSCC tumor suppressors: *TP53*, *CDKN2A*, and *NOTCH1/2*, including both truncating mutations and mutations at sites previously annotated in the COSMIC database (41). *TP53* was mutated in 23 of 29 (79%) samples, and *CDKN2A* was altered by both mutation and homozygous loss in 14 samples (48%). These findings, in addition to the lack of HPV sequences detected in the tumor DNA, agreed with the independent validation of a lack of HPV in our sample cohort. Lastly, *NOTCH* genes

Table 1. Cohort description

Gender	
Male	19
Female	10
Age at diagnosis of nodal metastasis, y (median; range)	74; 48–92
Immune status	
Immunocompromised	4
Not immunocompromised	25
Smoking	
Yes	12
No	17
Recurrence	
Yes	11
No	18
Received radiation therapy	
Yes	6
No	23
Prior diagnosis of cSCC	
Yes	12
No	17
PFS, months (median; range)	37; 1–130
Overall survival, months (median; range)	60; 7–155

**Figure 1.**

Integrated view of selected recurrently altered genes. A, genomic overview of sequencing and variant calling. The top three plots show the distribution of CNA types across the samples, distribution of SNV types across the samples, and the average coverage of tumor samples and their matched normal samples where available. B, heatmap representation of selected recurrently altered genes. CNAs are colored in red for high-level amplification events and green for homozygous deletion events. For simplicity, low-level CNA events are not shown. SNVs are colored by type in purple, beige, or blue, and also labeled: I, insertion or deletion (indel); S, missense; C, COSMIC; *, truncating; and O, other types of nonsynonymous mutation (splice site, nonstop). Significantly mutated genes as determined by Mutsig CV are those whose q-scores pass the threshold of 0.1 (or $-\log_{10}Q$ value greater than 1) on the left-hand plot. The genes are listed in order of decreasing number of alterations across the samples, as shown on the right-hand plot.

showed inactivating mutations in seven samples (24%), but if we included nonsynonymous SNVs of unknown functional significance, the rate increased to 69%, similar to the 75% rate noted previously (16).

RIPK4, a regulator of squamous epithelial differentiation, has been previously reported as recurrently mutated in head and neck SCCs (42). *RIPK4* was also recurrently altered in our cSCC cohort, with mutations in seven samples (24%). Two of these mutations were truncating, suggesting a recurrent inactivation of this gene. Another reported tumor suppressor in head and neck SCC is *SMAD4*, a gatekeeper gene that maintains genomic stability (43). Haploinsufficiency of *SMAD4* is thought to lead to genome instability as well as metastasis and inflammation. In our cohort, *SMAD4* had COSMIC mutations in two samples (7%).

There were known gain-of-function oncogene mutations in 11 of 29 samples (38%), though recurrent events were rare in our cohort (Fig. 3A, heatmap; Table 2). Two cases had *BRAF* mutations (G464R/G469R)—G469R, for example, has been reported in 1% of *BRAF*-mutated melanomas (44). One case had a *KRAS* G12C mutation and another had an *EGFR* S720F mutation; both are rare mutations previously identified in other types of SCC, including lung, anal, and tonsil (35, 45). An additional case had an *FGFR3* transmembrane domain G380R mutation that renders the protein constitutively active and is known to cause the autosomal-dominant disease achondroplasia (46). One case had a *KIT* exon 11 E562D mutation; exon 11 mutations are prevalent in 66% of gastrointestinal stromal tumors (47). Four additional mutations have also been validated as activating: *HRAS* G13D is common in bladder, thyroid, and kidney cancers (48); *ERBB4*

E563K is one of the *ERBB4* mutations reported in 19% of patients with melanoma (49); and *EZH2* Y641S is one of the most common recurrent mutations in certain types of lymphoma (50). The functional significance of *PIK3CA* P471L and *HGF* E199K is unclear; however, these two mutations were also observed in two of the 11 cSCC samples previously analyzed by next-generation sequencing (15). Mutations in the coiled-coil domain of *CARD11* have been described in diffuse large B-cell

Table 2. All functionally validated or likely activating mutations identified in metastatic cSCC samples

Gene	Mutation	Type
<i>BRAF</i>	G464R	Clinically relevant activating (rare in melanoma)
<i>BRAF</i>	G469R	Clinically relevant activating (1% of melanomas)
<i>KRAS</i>	G12C	Clinically relevant activating
<i>FGFR3</i>	G380R	Clinically relevant activating (94% of achondroplasia)
<i>KIT</i>	E562D	Functionally validated activating (exon 11 mutation in 60% of GISTs)
<i>HRAS</i>	G13D	Functionally validated activating
<i>EGFR</i>	S720F	Functionally validated activating (5% of non-small cell lung cancers)
<i>ERBB4</i>	E563K	Functionally validated activating
<i>EZH2</i>	Y641S	Functionally validated activating (22% of FLs)
<i>MTOR</i>	S221F	Functionally validated activating
<i>PIK3CA</i>	P471L	Likely activating (same mutation in ref. 15)
<i>HGF</i>	E199K	Likely activating (same mutation in ref. 15)
<i>CARD11</i>	E24K	Likely activating (gain-of-function mutations in CARD domains <i>in vitro</i>)
<i>CARD11</i>	D199N	Likely activating (gain-of-function mutations in CARD domains <i>in vitro</i>)

Abbreviations: FL, follicular lymphoma; GIST, gastrointestinal stromal tumor.

lymphoma (51) and recently, mutations in the CARD domain have been shown to disrupt CARD11 autoinhibition and activate the protein (52). Two of the *CARD11* mutations we observed (E24K, D199N) are located in this domain. It was interesting to note that nearly all of these mutations are mutually exclusive (Fig. 3A), in which each activating mutation belongs to a distinct tumor.

Half (48%) of the samples had truncating or COSMIC mutations in one or more chromatin remodeling genes. *CREBBP* and *EP300* are histone acetyltransferases and have truncating mutations in 6 and 3 samples, respectively. *EP300* is a known transcriptional coactivator of *NOTCH* pathway genes. Notably, the truncating mutations in *NOTCH1*, *NOTCH2*, *NOTCH4*, and *EP300* are mutually exclusive across the samples. *MLL2*, a histone methyltransferase that is frequently mutated in non-Hodgkin lymphomas (53), demonstrated nonsense mutations in five samples. Three members of *ARID* family gene transcription factors (*ARID1A*, *ARID2*, and *ARID5B*) had likely inactivating mutations in five samples, and *ARID2* was the mostly recurrently inactivated chromatin modifying enzyme with truncating mutations in 10% of cases. The SWI/SNF complex member *SMARCA4* had a splice site mutation in one sample. The *EZH2*-activating mutation Y641S as mentioned above was also seen in one sample. Thus, epigenetic dysregulation may be a recurrent oncogenic mechanism in metastatic cSCC.

Overview of CNAs

CNAs in the 504 cancer-associated genes were analyzed using GISTIC, which finds recurrent gains and losses against a multifactorial background (including length, amplitude, known fragile sites, surrounding sequence context, among other factors; ref. 36). We observed 25 significantly amplified and 11 significantly deleted genes using a standard GISTIC q-value threshold of 0.25 (Fig. 2). Peaks that cluster together (i.e., around *MYC*) suggest a potentially broader event, whereas isolated peaks containing only one gene (i.e., *TP63*) may indicate a more focal event.

The most significantly recurrent loss was at 9p21, including the cell cycle regulators *CDKN2A* and *CDKN2B*, which showed loss in

6 samples (21%). Numerous genes were recurrently gained across the samples, including the *MYC* and *EGFR* oncogenes. *TP63* was amplified in seven samples (24%), and has been previously observed at a similar frequency in lung SCCs (35). *TP63* has also been identified as an oncogene involved in squamous cell differentiation in mouse SCC models (54). We did not observe high-level (more than one copy) amplification of *PIK3CA* or *SOX2*, additional genes on chromosome 3q that have been implicated in the pathogenesis of squamous cell carcinomas (35).

When we focused on only the high-level amplifications, the most recurrently altered oncogene was *LAMA5*, in four samples. *LAMA5* may be associated with the metastatic nature of this patient cohort, as it is strongly expressed and promotes migration in melanoma cells (55).


Though there were tumor suppressors recurrently amplified, such as *FANCC* or *SDHB*, these may be passenger events for nearby genes that were not targeted in our hybrid capture panel.


Pathway overview and potential therapeutic targets

Many of most significant and functionally characterized somatic alterations we identified belong to cancer signaling pathways. We were able to categorize the SNVs and CNAs described above into four major categories: the RAS/RTK/PI3K pathway, cell cycle pathway, squamous cell differentiation pathway, and chromatin remodeling genes. We then examined the well-characterized pathways in a detailed supervised analysis to identify additional altered genes which could impact these core signaling pathways. We only included alterations that appeared to be pathway-activating (known activating mutation or high-level amplification), pathway-inactivating (nonsense mutation or homozygous loss), or likely functional (present in multiple COSMIC tumor samples).

The majority of the activating mutations affected genes in the RAS–RAF–MEK–ERK and PI3K/AKT pathways (Fig. 3A), for example, the receptor tyrosine kinases *FGFR3*, *KIT*, *EGFR*, *ERBB4*; receptor ligand *HGF*; RAS family members *KRAS*, *HRAS*; RAF family member *BRAF*, *MTOR*, and PI3K family member *PIK3CA*. Aside from an activating mutation, *EGFR* was also significantly

Figure 2. Overview of CNAs. GISTIC plot showing the most recurrently gained (red) and lost (blue) loci in metastatic cSCCs. Peaks are considered significant if they pass the q-value threshold of 0.25. The majority of peaks contain only one gene, as we determined CNAs using 504 cancer-associated genes.



**Figure 3.**

Recently altered pathways in metastatic cSCC. Pathway diagrams depicting the percentage of samples with alterations in (A) RAS/RAF/MEK/ERK and PI3K/AKT signaling, (B) cell cycle, and (C) squamous cell differentiation. Alterations are classified as activating (high-level amplification or known activating mutation colored red), inactivating (homozygous loss or truncating mutation colored blue), or potentially cancer associated (COSMIC mutation colored white). For each pathway, we show integrated heatmaps (similar to Fig. 1B) to show the detailed alteration pattern of each gene; however, we now also include light red and light green to represent low-level CNAs. Note that each heatmap is sorted independently across the samples, to best illustrate the pattern of mutations, such as mutual exclusivity or concurrence.

recurrently amplified (Fig. 2), though only one sample had a high-level gain (Fig. 3A). One sample had a nonsense *STK11* mutation in addition to a *TP53* nonsense mutation. *STK11* negatively regulates the PI3K/AKT pathway via AMPK-TSC1/2-mTOR, and loss of both *TP53* and *STK11* has been shown to induce lung SCC in mouse models (56). Two samples had a COSMIC mutation in the tumor suppressor *PTEN*, also a negative regulator of the PI3K/AKT pathway. Though only one was a truncating mutation, the other was also a likely inactivating mutation as both are seen in numerous (~60) samples in COSMIC. *NF1* is a negative regulator of RAS and had a COSMIC mutation in 3 samples (10%). The heatmap in Fig. 3A illustrates the trend toward mutual exclusivity for these pathway alterations.

Aside from *TP53* and *CDKN2A*, we found recurrent alterations in other cell cycle pathway genes, including *RB1*, *MYC*, *CDK4*, *CDK6*, and *CCND1* (Fig. 3B). *MYC* was amplified in 10 samples, though only highly amplified in one, whereas *CCND1* was

amplified in four. Two samples each had a high-level gain in *CDK4* and *CDK6*, respectively. One sample had a nonsense mutation in *ATR*, for which truncating mutations are recurrent in endometrial cancers and associated with a poorer overall survival (57).

Numerous genes involved in the squamous cell differentiation pathway were recurrently altered in our cohort (Fig. 3C). *TP63* amplification, *NOTCH1* and *NOTCH2* mutations have been previously reported in lung as well as head and neck SCCs (35, 42). Inactivation of the NF- κ B pathway, which is required for keratinocyte differentiation *in vivo* (58), is also implicated via mutations in *RIPK4*, amplifications of *TP63* (transcriptional activator of *RIPK4*) and *NFKB1A*. There are also amplifications and activating mutations in *CARD11* that appear to activate the NF- κ B pathway based on previous reports (59). *SMAD4* is a gatekeeper gene in head and neck SCC, as shown in studies where knockout mice developed spontaneous head and neck SCC (43) or induced

differentiation of mammary epithelial cells into squamous epithelial cells, leading to SCC (60). In our cohort, one sample in which we detected no *TP53*, *NOTCH 1/2/4*, or oncogenic activating mutations had a *CDKN2A* COSMIC missense mutation and a *SMAD4* nonsense mutation.

In short, though no highly recurrent mutation was identified, we found that mutations activating the RAS/RTK/PI3K, cell cycle, and squamous cell differentiation pathways are recurrent across the samples and present opportunities for biomarker-driven clinical trials in this patient cohort.

Genomic or clinical factors correlated to prognosis

In an exploratory analysis, we searched for correlations between the significantly altered genes in Fig. 1B and the clinical factors listed in Table 1 such as recurrence and PFS. There was a trend for immunocompromised patients to have recurrence and worse prognosis (log rank *P* value of 0.017); however, the small number of immunocompromised patients (*n* = 4) limits this observation. Similarly, the lack of a validation cohort in the literature significantly dampens enthusiasm for clinical correlations found in our work.

No single gene significantly correlated with a clinical factor. A broader analysis of all genes altered more than three times in our cohort revealed hypothesis-forming associations between *ARID5B* and *CARD11* alterations and PFS (Supplementary

Fig. S1). The association of *CARD11*-activating mutations or amplifications with a better prognosis is interesting given that these alterations likely activate the NF- κ B pathway and promote differentiation.

Given that alterations causing RAS pathway activation, cell cycle pathway inactivation, squamous cell differentiation, and chromatin remodeling gene inactivation are recurrent across the metastatic cSCC samples, we assessed whether these pathways correlated with a clinical factor. There was no correlation between the cell cycle alterations (in *TP53* or *CDKN2A*) nor the squamous differentiation alterations (in *TP63*, *NOTCH1*, or *NOTCH2*) and prognosis or other clinical variables. In contrast, both the RAS/RTK/PI3K pathway and chromatin remodeling mutations were significantly correlated with a worse prognosis, and a combination of both types of mutations increased the significance of the correlation, suggesting that these may be independent predictors (Fig. 4). We chose functionally or clinically relevant RAS/RTK/PI3K alterations that are known or very likely to be activating the pathway (those circled in Fig. 3A and also present in Table 2) with the exception of the *EGFR* and *ERBB4* mutations, which were instead associated with a long PFS. The average PFS for RAS/RTK/PI3K pathway-mutated samples without *EGFR/ERBB4* mutations was 12 months, for non-RAS/RTK/PI3K pathway-mutated samples was 50 months, and for the *EGFR/ERBB4* samples was 79 months. Similarly, we chose chromatin remodeling mutations




Figure 4.

Alterations in the RTK/RAS/PI3K pathway and chromatin remodeling genes associated with PFS in metastatic cSCC. The Kaplan-Meier survival curves of patients with metastatic cSCC comparing patients with or without mutation in (A) RTK/RAS/PI3K pathway, (B) chromatin remodeling genes, or (C) both.

that were likely to be functionally relevant; this included truncating mutations in *ARID2* and *NF2*, and missense mutations in *EZH2* and *SMARCB1* that were previously seen in COSMIC. The chromatin remodeling gene mutations correlated with a worse PFS and suggest that epigenetic dysregulation plays a role in metastatic cSCC.

Analysis of overall survival data supported the correlation among samples with mutations in chromatin modifiers or mutations with chromatin modifiers and/or RAS/RTK/PI3K and poor outcome, though the correlation among RAS/RTK/PI3K and poor outcome was not supported (Supplementary Fig. S2). A much larger sample size would be needed to characterize these observations further.

Discussion

The cohort in this study represents the rare 5% of cSCC tumors that have metastasized and have a poor clinical prognosis. Of the 29 patients studied, 11 exhibited recurrence within an average of 24 months. However, the actual times to recurrence varied from 1 month to 78 months, and some patients are still recurrence-free at 130 months. This suggests that there may be genomic or clinical features that can distinguish between these two types of prognoses within the metastatic cohort. The frequency of recurrence also underscores the need for improved therapeutic options for this patient population.

We identified recurrent somatic mutations and CNAs in metastatic cSCCs. The top three recurrently altered genes are *TP53*, *CDKN2A*, and *NOTCH1/2/4*, at frequencies similar to previous reports of both cSCCs (15, 16, 21, 22) and squamous cancers from other sites such as lung or HPV-negative head and neck (31, 32, 42, 61). *TP53* was mutated in 79% of samples, *CDKN2A* altered in 48%, and *NOTCH1/2/4* in 69%. The prevalence of somatic *TP53* mutations is in concordance with the HPV-negative assessment of the samples, as the E6 protein of HPV binds to *TP53* and marks it for degradation—an independent mechanism from mutational inactivation. Unlike the *TP53* and *CDKN2A* mutations, the majority of *NOTCH* mutations were missense mutations not present in COSMIC. Thus, given the high mutation rate in this tumor type (33 mutations per Mb cancer-associated coding sequence), it may be more conservative to estimate that *NOTCH* family members are inactivated in approximately 25% of our metastatic cSCC cohort. It should also be mentioned that *TP53*, *CDKN2A*, and *NOTCH* genes can be inactivated by mechanisms other than somatic mutation and deletion and that the rates of loss of these genes may be higher than that observed in the context of our analysis.

Oncogenic alterations activating the RAS/RTK/PI3K pathway were present in 45% of samples and—aside from *EGFR/ERBB4* mutations—significantly correlated with a worse PFS. Currently, the principal target being evaluated in clinical trials in cSCC is *EGFR* with some clinical activity reported to date but no prospectively validated biomarker for patient selection. In our dataset, we observed two samples with potential *EGFR* activation: one with a rare *EGFR*-activating mutation and a second with high-level amplification. However, numerous samples had activations in other receptor tyrosine kinases (*KIT*, *FGFR3*, *ERBB4*), downstream kinases (*KRAS*, *HRAS*, *BRAF*), and genes in the PI3K/AKT pathway (*MTOR*, *PIK3CA*, *PTEN*, *STK11*). These potential targets are currently being investigated in clinical trials of other tumor types, and we feel that including patients with cSCCs should be considered.

Given that (i) many of these alterations converge on key downstream mediators of cellular survival and proliferation such as MEK and mTOR, (ii) recent data from other groups showing that combined BRAF and MEK inhibition blocked proliferation in a mouse model of cSCC (62), and (iii) mTOR-based inhibitors reduced the risk of developing cSCCs in immunocompromised patients (63), we feel that evaluation of such strategies for patients with cSCCs is warranted.

The alterations identified in our cohort exhibit similarities to other SCCs studied to date. Somatic alterations activating *PIK3CA*, *HRAS*, *TP63*, *CCND1*, *EGFR*, *MYC*, and inactivating *TP53*, *CDKN2A*, *NOTCH1*, *NOTCH2*, *RIPK4*, and *SMAD4* have been previously described in head and neck SCC (42, 61). In particular, mutations of *TP53* almost exclusively occurred in HPV-negative head and neck SCCs, which is consistent with the HPV-negative nature of our cohort. Lung SCC has also been noted to be similar to HPV-negative head and neck SCC, with mutations in *PIK3CA*, *PTEN*, *TP53*, *CDKN2A*, *NOTCH1*, and *HRAS* (35), which are shared in metastatic cSCC. In esophageal SCC, mutations in *TP53*, *CDKN2A*, and *NOTCH1* are also recurrent, and a recent study has identified frequent dysregulation in RTK–MAPK–PI3K signaling, G₁–S cell cycle regulation, and epigenetic modification (64). Numerous other recurrent alterations have been identified in SCCs—for example, *ASCL4* loss-of-function mutations and *FOXP1* focal deletions in lung SCC; however, these genes were not part of our targeted panel.

Recent exome sequencing of a cohort of 39 clinically aggressive cSCC primary tumors that presented with metastases found no clinically targetable oncogenes, though nonsynonymous mutations in the oncogenes *HRAS* and *STK19* were identified (21). Similarly, targeted sequencing of 100 cSCC primary tumors confirmed previous rates of recurrent tumor suppressor mutations but did not identify recurrent oncogenic mutations aside from *KNSTRN* (22). In our targeted sequencing cohort of 29 metastatic tumors, we found gain-of-function mutations in 12 oncogenes across 13 samples, including clinically targetable *BRAF*, *FGFR3*, *PIK3CA*, and *EGFR* mutations. In addition, two kinase mutations in our cohort, *PIK3CA* P471L and *HGF* E199K, and *NOTCH4* W309* were previously identified in a cohort of 11 primary cSCCs, suggesting that these mutations may have functional roles in metastatic cSCCs. Along these lines, other oncogenic mutations may also be recurrent at a low prevalence. Thus, larger cohort studies are necessary to identify both recurrent and more unique oncogenic alterations. Assessment of the whole genome, transcriptome, and methylome on a future cohort may also identify relevant structural variations, alterations in other cancer-associated genes, mutations in non-coding regions, or methylated genes. However, comprehensive transcriptome sequencing may be challenging given the rarity of metastatic cSCC cases.

In short, we have sequenced a rare cohort of metastatic cSCCs and identified a wide spectrum of oncogenic mutations in known oncogenes and tumor suppressors novel to this tumor type. These mutations mostly fell in the RAS/RTK/PI3K pathway and chromatin remodeling genes, and appeared to be significantly correlated with PFS within patients with metastatic cSCC. The results of our study suggest that agents currently undergoing investigation in clinical studies for other cancer types (such as MEK/mTOR/FGFR/BRAF/PI3K inhibitors) should be considered for individuals with cSCC, and given the similarity among the genomic alterations found in cSCC, HPV-negative squamous

cell carcinoma of the head and neck, and lung SCC, it may be prudent to include patients with SCCs of various sites of origin in clinical studies. Many of the mutations we identified in metastatic cSCCs were not previously seen in genomic studies of primary cSCCs; however, more studies of larger cohorts will be needed to differentiate the genomic events important to each type of tumor. Given the rare nature of this cohort, our analysis was limited by the quality of material available for analysis, and suboptimal sequencing coverage in some of the samples may have limited our ability to detect important genomic alterations. Further, the use of more global analysis techniques such as whole-exome, whole-genome, or transcriptome sequencing on larger cohorts of patients with cutaneous SCCs will be needed to provide a more complete understanding of the most critical genomic alterations in this disease.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: R.I. Haddad, J.H. Lorch, P.S. Hammerman

Development of methodology: J.H. Lorch, P.S. Hammerman

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G.J. Hanna, R.I. Haddad, J.H. Lorch

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y.Y. Li, G.J. Hanna, R.I. Haddad, J.H. Lorch, P.S. Hammerman

Writing, review, and/or revision of the manuscript: Y.Y. Li, A.C. Laga, R.I. Haddad, J.H. Lorch, P.S. Hammerman

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.C. Laga, J.H. Lorch, P.S. Hammerman

Study supervision: J.H. Lorch, P.S. Hammerman

Other (reviewed the histopathology of all cases studied, confirmed or revised the diagnosis, and selected tumor areas for microdissection and genomic studies): A.C. Laga

Acknowledgments

The authors thank the Dana-Farber Cancer Institute Center for Genome Discovery (P. van Hummelen, A. Thorner, M. Ducar, B. Wollison) for assistance with sample processing and analysis and the Pathology Core (C. Namgyal) at the Brigham and Women's Hospital for assistance with the tissue blocks.

Grant Support

P.S. Hammerman is supported by NCI K08 CA163677. J.H. Lorch is supported by a Friends of Dana Farber Grant.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 10, 2014; revised December 23, 2014; accepted December 29, 2014; published OnlineFirst January 14, 2015.

References

- Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol* 2010;146:283-7.
- Karia PS, Han J, Shumults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. *J Am Acad Dermatol* 2013;68:957-66.
- Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. *Arch Dermatol* 2003;139:301-6.
- Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. *J Am Acad Dermatol* 1992;26:976-90.
- Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. *J Am Acad Dermatol* 1992;26:1-26.
- Joseph MG, Zulueta WP, Kennedy PJ. Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. *ANZ J Surg* 1992;62:697-701.
- Kraus DH, Carew JF, Harrison LB. Regional lymph node metastasis from cutaneous squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 1998;124:582-7.
- Alam M, Ratner D. Cutaneous squamous-cell carcinoma. *N Engl J Med* 2001;344:975-83.
- Criscone VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, et al. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial. *Cancer* 2009;115:2523-30.
- Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002;47:1-17; quiz 8-20.
- Iannaccone MR, Gheit T, Waterboer T, Giuliano AR, Messina JL, Fenske NA, et al. Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. *Cancer Epidemiol Biomarkers Prev* 2012;21:1303-13.
- Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. *J Clin Oncol* 2012;30:316-21.
- Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. *Lancet Oncol* 2008;9:713-20.
- Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Shumults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. *J Clin Oncol* 2014;32:327-34.
- Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, Collisson EA, et al. Temporal dissection of tumorigenesis in primary cancers. *Cancer Discov* 2011;1:137-43.
- Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. *Proc Natl Acad Sci U S A* 2011;108:17761-6.
- Purdie KJ, Harwood CA, Gulati A, Chaplin T, Lambert SR, Cerio R, et al. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. *J Invest Dermatol* 2009;129:1562-8.
- Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. *J Invest Dermatol* 2004;122:1284-92.
- Lambert SR, Mladkova N, Gulati A, Hamoudi R, Purdie K, Cerio R, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. *Br J Cancer* 2014;110:520-9.
- South AP, Purdie KJ, Watt SA, Haldenby S, den Breems NY, Dimon M, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. *J Invest Dermatol* 2014;134:2630-8.
- Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. *Clin Cancer Res* 2014;20:6582-92.
- Lee CS, Bhaduri A, Mah A, Johnson WL, Ungewickell A, Aros CJ, et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. *Nat Genet* 2014;46:1060-2.
- Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. *J Exp Med* 2005;201:1089-99.

24. Ch'ng S, Low I, Ng D, Brasch H, Sullivan M, Davis P, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. *Hum Pathol* 2008;39:344–9.
25. Maurer A, Herschberger E, Dietmaier W, Landthaler M, Hafner C. Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. *Exp Dermatol* 2011;20:848–50.
26. Alter M, Satzger I, Mattern A, Kapp A, Gutzmer R. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. *Dermatology* 2013;227:289–94.
27. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. *Clin Cancer Res* 2012;18:1435–46.
28. Abedalthagafi MS, Merrill PH, Bi WL, Jones RT, Listewnik ML, Ramkissoon SH, et al. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. *Oncotarget*. 2014;5:10596–606.
29. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. *Cancer Discov* 2012;2:82–93.
30. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* 2013;31:213–9.
31. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–50.
32. Seiwert TY, Zuo Z, Keck MK, Khattari A, Pedamallu CS, Stricker TP, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. *Clin Cancer Res* 2014 Jul 23. [Epub ahead of print].
33. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. *J Clin Oncol* 2014;32:121–8.
34. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012;150:1107–20.
35. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–25.
36. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhi R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol* 2011;12:R41.
37. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. *Nat Genet* 2013;45:1134–40.
38. Daya-Grosjean L, Sarasin A. The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. *Mutat Res* 2005;571:43–56.
39. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nat Genet* 2013;45:970–6.
40. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013;499:214–8.
41. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res* 2011;39:D945–50.
42. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. *Science* 2011;333:1157–60.
43. Korc M. Smad4: gatekeeper gene in head and neck squamous cell carcinoma. *J Clin Invest* 2009;119:3208–11.
44. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. *PloS One* 2007;2:e236.
45. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. *BMC Cancer* 2010;10:189.
46. Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, Horton WA, Machado M, et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. *Am J Hum Genet* 1995;56:368–73.
47. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. *J Clin Oncol* 2004;22:3813–25.
48. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. *J Natl Cancer Inst* 2001;93:1062–74.
49. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinase in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* 2009;41:1127–32.
50. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* 2010;42:181–5.
51. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science* 2008;319:1676–9.
52. Chan W, Schaffer TB, Pomerantz JL. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival. *Mol Cell Biol* 2013;33:429–43.
53. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* 2011;476:298–303.
54. Ramsey MR, Wilson C, Ory B, Rothenberg SM, Faquin W, Mills AA, et al. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. *J Clin Invest* 2013;123:3525–38.
55. Oikawa Y, Hansson J, Sasaki T, Rousselle P, Domogatskaya A, Rodin S, et al. Melanoma cells produce multiple laminin isoforms and strongly migrate on alpha5 laminin(s) via several integrin receptors. *Exp Cell Res* 2011;317:1119–33.
56. Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. *Cancer Cell* 2014;25:590–604.
57. Zigelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. *J Clin Oncol* 2009;27:3091–6.
58. Adams S, Pankow S, Werner S, Munz B. Regulation of NF-kappaB activity and keratinocyte differentiation by the RIP4 protein: implications for cutaneous wound repair. *J Invest Dermatol* 2007;127:538–44.
59. Pomerantz JL, Denny EM, Baltimore D. CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. *EMBO J* 2002;21:5184–94.
60. Li W, Qiao W, Chen L, Xu X, Yang X, Li D, et al. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. *Development* 2003;130:6143–53.
61. Agrawal N, Frederick MJ, Pickering CR, Bettgeowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 2011;333:1154–7.
62. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N Engl J Med* 2012;366:207–15.
63. Karayannopoulou G, Euvrard S, Kanitakis J. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients. *Anticancer Res* 2013;33:3711–4.
64. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. *Nat Genet* 2014;46:467–73.